172 related articles for article (PubMed ID: 17901830)
1. The alphabet soup of chemotherapy.
Dinman S
Plast Surg Nurs; 2007; 27(3):173-5. PubMed ID: 17901830
[No Abstract] [Full Text] [Related]
2. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
Booth CM; Pater JL; Goss PE
Cancer; 2007 May; 109(9):1927-8; author reply 1928. PubMed ID: 17354227
[No Abstract] [Full Text] [Related]
3. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
4. Hormonal breast cancer agents: implications for the primary care provider.
Lyon DE; Roux G; Voll S
J Am Acad Nurse Pract; 2006 Nov; 18(11):518-23. PubMed ID: 17064329
[TBL] [Abstract][Full Text] [Related]
5. Toremifene citrate (Fareston).
Gerken P
Clin J Oncol Nurs; 2004 Oct; 8(5):529-30. PubMed ID: 15565747
[No Abstract] [Full Text] [Related]
6. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Dixon JM
Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
[TBL] [Abstract][Full Text] [Related]
7. Management of early breast cancer--the current approach.
Brennan M; Wilcken N; French J; Ung O; Boyages J
Aust Fam Physician; 2005 Sep; 34(9):755-60. PubMed ID: 16184208
[TBL] [Abstract][Full Text] [Related]
8. Adherence to oral endocrine therapy for breast cancer: a nursing perspective.
Miaskowski C; Shockney L; Chlebowski RT
Clin J Oncol Nurs; 2008 Apr; 12(2):213-21. PubMed ID: 18390458
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment.
Viale PH
Oncol Nurs Forum; 2005 Mar; 32(2):343-53. PubMed ID: 15759071
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of endocrine therapy for early stage breast cancer.
Manders JB; Gradishar WJ
Breast Cancer; 2005; 12(2):62-72. PubMed ID: 15858435
[No Abstract] [Full Text] [Related]
11. Estrogen-receptor biology: continuing progress and therapeutic implications.
Osborne CK; Schiff R
J Clin Oncol; 2005 Mar; 23(8):1616-22. PubMed ID: 15755967
[No Abstract] [Full Text] [Related]
12. [Adjuvant endocrine therapy in premenopausal breast cancer].
Bando H
Nihon Rinsho; 2012 Sep; 70 Suppl 7():627-35. PubMed ID: 23350475
[No Abstract] [Full Text] [Related]
13. Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all?
Jordan VC
J Clin Oncol; 2005 Mar; 23(8):1598-600. PubMed ID: 15755960
[No Abstract] [Full Text] [Related]
14. Radiation therapy for invasive breast cancer: not just for local control.
Harris JR
J Clin Oncol; 2005 Mar; 23(8):1607-8. PubMed ID: 15755963
[No Abstract] [Full Text] [Related]
15. Aromatase inhibitors as adjuvant therapy for breast cancer.
Montemurro F; Aglietta M; Del Mastro L
J Clin Oncol; 2009 May; 27(15):2566-7. PubMed ID: 19332706
[No Abstract] [Full Text] [Related]
16. [Nurse's role in chemotherapy care].
Rovelon P
Soins; 2003 Mar; (673):37-9. PubMed ID: 12677922
[No Abstract] [Full Text] [Related]
17. Chemotherapy-related amenorrhea in premenopausal women with breast cancer.
Lee S; Kil WJ; Chun M; Jung YS; Kang SY; Kang SH; Oh YT
Menopause; 2009; 16(1):98-103. PubMed ID: 18849877
[TBL] [Abstract][Full Text] [Related]
18. Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Paydas S
Leuk Res; 2009 Apr; 33(4):566-7. PubMed ID: 18585780
[No Abstract] [Full Text] [Related]
19. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Mamounas EP
Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
[TBL] [Abstract][Full Text] [Related]
20. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
